FINWIRES · TerminalLIVE
FINWIRES

Island Pharmaceuticals Signs Statement of Work With Texas Biomed to Advance Galidesivir, Shares Hit Six Month High

By

Island Pharmaceuticals (ASX:ILA) executed a statement of work (SOW) with the Texas Biomedical Research Institute to further advance Galidesivir's Animal Rule development for the treatment of Marburg Virus Disease, according to a Monday Australian bourse filing.

Galidesivir is the company's clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola and Marburg, with the SOW providing the opportunity to advance a complementary Food and Drug Administration-directed dose optimisation study in a further 12 non-human primates.

The company's shares rose 10% in recent Monday trade, reaching their highest price since December 2025.

Related Articles

Asia

GAC Warns of Wider Loss in H1

Guangzhou Automobile Group or GAC (HKG:2238, SHA:601238) expects an attributable loss of between 4.06 billion yuan and 4.57 billion yuan for the first half of 2026, wider than 2.54 billion yuan a year prior.The automaker attributed the forecast to a wider loss from self-developed brands, lower investment income, and foreign exchange losses, according to a Friday Hong Kong bourse filing.

HKG:2238SHA:601238
Asia

Jiumaojiu International Posts Mixed Same-Store Daily Sales in Q2

Jiumaojiu International Holdings (HKG:9922) posted mixed results for same-store average daily sales across major brands in the second quarter of 2026, according to a Friday Hong Kong bourse filing.Self-operated Tai Er stores recorded a 6.1% rise in same-store average daily sales. On the other hand, Song Hot Pot fell 26% and Jiu Mao Jiu declined 14%.As of June 30, Jiumaojiu operated 606 restaurants, including 477 Tai Er outlets.Average spending per customer across major brands has remained relatively stable for several consecutive quarters.

HKG:9922
Asia

CSSC Offshore & Marine Engineering Forecasts Up to 69% Surge in H1 Profit

CSSC Offshore & Marine Engineering (HKG:0317, SHA:600685) expects an attributable profit of between 790 million yuan and 890 million yuan for the first half of 2026, up 50% to 69% from 526.4 million yuan a year prior.The marine and defense equipment manufacturer attributed the forecast to a rise in product gross profit amid production and operational efficiency, as well as higher recognized investment income.

HKG:0317SHA:600685